FendX Provides Corporate Update

• FendX announced operational progress on its liquid surface coating and Foley catheter coating programs, including newly filed provisional patents for both technologies and an AI-driven surface contamination detection app.
• The company terminated prior license agreements with McMaster University to eliminate future royalty/licensing payments, signaling a strategic pivot away from the REPELWRAP film product to focus exclusively on the liquid formulation.
• A formal collaboration agreement with Aquaox LLC was executed to assess the technical feasibility of eco-friendly antimicrobial agents for consumer, commercial, and healthcare applications.
• FendX will settle $89,578 in outstanding consulting fees by issuing 242,102 common shares at a deemed price of $0.37 per share, pending regulatory approval.
• Investor relations services with Outside The Box Capital Inc. were renewed through June 30, 2026, with a negotiated fee reduction of $28,080 at no additional cost to the company.

• The update is administrative and developmental in nature, containing no near-term revenue generation, commercial contracts, or binding supply agreements.
• License terminations with McMaster reduce future cash outflows but simultaneously confirm the abandonment of the REPELWRAP film initiative, which previously represented a core commercialization pathway.
• The share-for-debt settlement at $0.37 per share represents continued equity dilution to preserve cash, a common but structurally negative practice for pre-revenue micro-caps.
• The Aquaox collaboration remains strictly at the feasibility assessment stage with explicit disclaimers noting no guarantee of definitive agreements, regulatory approvals, or commercial products.
• Overall, the news is incremental, aligns with prior disclosures, and lacks the financial or operational scale required to move the stock materially.

• FendX Technologies Inc. is a pre-revenue Canadian micro-cap focused on antimicrobial surface protection technologies for healthcare, consumer, and commercial markets.
• Flagship project: A nanoparticle-based liquid surface coating designed for long-lasting pathogen control on high-touch surfaces, applicable via rollers or brushes. The company has filed a provisional patent for this formulation and is prioritizing scale-up and distribution partnerships.
• Secondary initiatives include a Foley catheter coating program (provisional patent filed, third-party testing planned) and an AI-driven surface contamination detection mobile application (provisional patent filed, beta testing anticipated).
• The company has explicitly deprioritized its REPELWRAP film product following the termination of related McMaster University licenses.